Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.

Abstract:

PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive, lethal, and heterogeneous subtype of breast cancers, tending to have lower 5-year survival rates than other BC subtypes in response to conventional chemotherapies. This study's aim was to identify advanced regimens to effectively control TNBC tumor development. METHODS:We investigated the combination of the DNA synthesis inhibitor gemcitabine, the DNA-damaging agent cisplatin, and the histone deacetylase inhibitor romidepsin to control a variety of breast cells in vitro. We studied the toxicity of drug doses and administration schedules to determine tolerable combination regimens in immune-deficient nude and -competent BALB/c mice. We then studied the efficacy of tolerable regimens in controlling TNBC cell-derived xenograft development in nude mice. By reducing clinically equivalent doses of each agent in combination, we formulated tolerable regimens in animals. We verified that the tolerable triple combination gemcitabine plus romidepsin + cisplatin regimen more efficacious than double combination regimens in controlling xenograft tumor development in nude mice. RESULTS:A triple combination of gemcitabine + romidepsin + cisplatin synergistically induced death of the TNBC M.D. Anderson-Metastatic Breast cancer (MDA-MB) 231 and MDA-MB468, as well as Michigan Cancer Foundation (MCF) 7, MCF10A, and MCF10A-Ras cells. Cell death induced by gemcitabine + romidepsin + cisplatin was in a reactive oxygen species-dependent manner. CONCLUSION:Considering the high costs for developing a new anticancer agent, we used the FDA-approved drugs gemcitabine, romidepsin (is approved for T-cell lymphoma and is under clinical trial for TNBC), and cisplatin to economically formulate an efficacious and safe combination regimen. The highly efficacious gemcitabine plus romidepsin + cisplatin regimen should be poised for efficient translation into clinical trials, ultimately contributing to reduced mortality and improved quality of life for TNBC patients.

authors

Pattarawat P,Wallace S,Pfisterer B,Odoi A,Wang HR

doi

10.1007/s00280-019-04013-y

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

141-152

issue

1

eissn

0344-5704

issn

1432-0843

pii

10.1007/s00280-019-04013-y

journal_volume

85

pub_type

杂志文章
  • Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.

    abstract:PURPOSE:To evaluate the efficacy and safety of preoperative radiotherapy with capecitabine and mitomycin C in patients with locally advanced rectal cancer. METHODS:A prospective, open-label, non-randomized, phase II study was performed on 49 patients with locally advanced rectal cancer. Preoperative radiotherapy was c...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00280-010-1469-8

    authors: Stojanovic S,Popov I,Radosevic-Jelic L,Micev M,Borojevic N,Nikolic V,Krivokapic Z,Kecmanovic D,Gavrilovic D,Kezic I

    更新日期:2011-09-01 00:00:00

  • Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.

    abstract:PURPOSE:RSR13, 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methylpropanoic acid monosodium salt, allosterically modifies hemoglobin to increase tumor pO(2), increases the effect of radiation in animal tumor models, and is in phase III clinical trials as an adjuvant to radiotherapy. Cisplatin and carboplat...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0715-8

    authors: Donnelly ET,Kelley M,Rockwell S

    更新日期:2004-01-01 00:00:00

  • Inhibition of cellular esterases by the antitumour imidazotetrazines mitozolomide and temozolomide: demonstration by flow cytometry and conventional spectrofluorimetry.

    abstract::Using flow cytometry and conventional spectrofluorimetry we have previously shown that chloroethylnitrosoureas (CNUs) can exhibit marked inhibition of cellular enzymes catalysing hydrolysis of fluorescein diacetate (FDA). More potent inhibition was seen for the carbamoylating CNUs, whereas alkylating agents were large...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689574

    authors: Dive C,Workman P,Watson JV

    更新日期:1989-01-01 00:00:00

  • Inhibition of intracellular Ca2+ signalling, cytotoxicity and antitumor activity of the herbicide oryzalin and its analogues.

    abstract:PURPOSE:Studies were conducted on oryzalin (3,5-dinitro-N,N-di(n-propyl)sulfanilamide), a widely used dinitroaniline sulfonamide herbicide, which was identified from plant extracts as an inhibitor of mitogen- and growth factor-mediated intracellular free Ca2+ ([Ca2+]i) signalling in mammalian cells. METHODS AND RESULT...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050703

    authors: Powis G,Gallegos A,Abraham RT,Ashendel CL,Zalkow LH,Dorr R,Dvorakova K,Salmon S,Harrison S,Worzalla J

    更新日期:1997-01-01 00:00:00

  • A clinical study of nafazatrom in advanced human breast cancer.

    abstract::Prostaglandins (PGs) have been shown to inhibit tumour metastases in experimental animal systems. Nafazatrom is a pyrazolinone derivative that increases endogenous prostacyclin (PGI2) and has experimental anti-cancer activity. In the present study, nafazatrom was given to 47 women with advanced breast cancer; objectiv...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/BF00685120

    authors: Jones AL,Powles TJ,Forgeson GV,Coombes RC

    更新日期:1991-01-01 00:00:00

  • Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities.

    abstract::A total of 51 patients with large, primary, high-grade soft-tissue sarcomas of the extremities were treated at our institute with two preoperative and three postoperative cycles of doxorubicin plus ifosfamide/mesna. Preoperative doxorubicin was given intra-arterially for lesions of the lower extremities. Of 47 evaluab...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Azzarelli A,Quagliuolo V,Casali P,Fissi S,Montalto F,Santoro A

    更新日期:1993-01-01 00:00:00

  • Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.

    abstract:PURPOSE:There is considerable current interest in the use of thalidomide as a single agent or in combination with drugs such as cyclophosphamide in the treatment of multiple myeloma and other cancers. Our previous work has shown that thalidomide potentiates the antitumour activity of both cyclophosphamide and 5,6-dimet...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0753-2

    authors: Chung F,Wang LC,Kestell P,Baguley BC,Ching LM

    更新日期:2004-05-01 00:00:00

  • The pharmacologic fate of the antitumor agent 2-amino-1,3,4-thiadiazole in the dog.

    abstract::Anticipating the renewed clinical trial of the antitumor agent 2-amino-1,3,4-thiadiazole (AT, NSC-4728), we have studied the pharmacologic fate of AT-5-14C in beagle dogs. The drug was only minimally metabolized in 5 h; the radioactivities in the urine, and particularly in the plasma, resided almost entirely in unchan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00255274

    authors: Lu K,Loo TL

    更新日期:1980-01-01 00:00:00

  • Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment?

    abstract::There is no argument over using epidermal growth factor receptor (EGFR) mutation status to guide the frontline treatment for advanced lung adenocarcinoma (LADC); however, the role of the testing in lung squamous cell carcinoma (LSQC) remains controversial. Currently, the guidelines/consensus statements regarding EGFR ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-014-2536-3

    authors: Chiu CH,Chou TY,Chiang CL,Tsai CM

    更新日期:2014-10-01 00:00:00

  • Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.

    abstract::Paclitaxel is used as a single agent, and in combination with other drugs, as a standard of care in the treatment of squamous cell carcinoma of the head and neck (SCCHN). However, the use of paclitaxel for therapy of SCCHN may be accompanied by serious side effects. Paclitaxel is a known cytotoxic inhibitor of cell pr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-004-0929-4

    authors: Jaglowski JR,Zagon IS,Stack BC Jr,Verderame MF,Leure-duPree AE,Manning JD,McLaughlin PJ

    更新日期:2005-07-01 00:00:00

  • The antitumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice.

    abstract::The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258113

    authors: Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

    更新日期:1985-01-01 00:00:00

  • A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

    abstract:PURPOSE:This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS:We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received placebo on day 1 and ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-1942-7

    authors: Lush RM,Patnaik A,Sullivan D,Papadopoulos KP,Trucksis M,McCrea J,Cerchio K,Li X,Stroh M,Selverian D,Orford K,Ebbinghaus S,Agrawal N,Iwamoto M,Wagner JA,Tolcher A

    更新日期:2012-10-01 00:00:00

  • Pharmacokinetics and toxicity of mitomycin C in rodents, given alone, in combination, or after induction of microsomal drug metabolism.

    abstract::The pharmacokinetics of mitomycin (MMC) was studied in Wistar rats. Up to five half-lives, the plasma concentration-time curve was biphasic. The AUC changed linearly with increasing doses between 0.5 and 7.5 mg/kg, which corresponds to 0.2 and 3 times the LD50 value in rats. Most of the drug was metabolized, and only ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257305

    authors: Kerpel-Fronius S,Verwey J,Stuurman M,Kanyár B,Lelieveld P,Pinedo HM

    更新日期:1988-01-01 00:00:00

  • Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.

    abstract::To evaluate toxicity and efficacy of chemotherapy in elderly patients (> or = 65 years of age) with advanced colorectal cancer, data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed comparing the results of treatment in those 65 years of age or old...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/s002800050826

    authors: Chiara S,Nobile MT,Vincenti M,Lionetto R,Gozza A,Barzacchi MC,Sanguineti O,Repetto L,Rosso R

    更新日期:1998-01-01 00:00:00

  • Studies on the mechanism of cytotoxicity of 3-deazaguanosine in human cancer cells.

    abstract::The mechanism of toxicity of 3-deazaguanosine was studied in a number of human tumor cell lines by determination of the effects of various purine compounds on the growth of the cells in the presence of the drug and by studies of the effects of 3-deazaguanosine on the metabolism of radiolabeled precursors in these cell...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00257296

    authors: Page T,Jacobsen SJ,Smejkal RM,Scheele J,Nyhan WL,Mangum JH,Robins RK

    更新日期:1985-01-01 00:00:00

  • Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide.

    abstract:PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0482-y

    authors: Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

    更新日期:2002-09-01 00:00:00

  • Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study.

    abstract:PURPOSE:The aim of the present study was to develop a new strategy for combined thermo-chemotherapy of cancer. For this purpose, we used ultrasound waves [1 MHz; 1 W/cm2; 10 min] in combination with a sonosensitizing nanoplatform, named ACA, made of alginate co-loaded with cisplatin and gold nanoparticles (AuNPs). MET...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03961-9

    authors: Irajirad R,Ahmadi A,Najafabad BK,Abed Z,Sheervalilou R,Khoei S,Shiran MB,Ghaznavi H,Shakeri-Zadeh A

    更新日期:2019-12-01 00:00:00

  • Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients.

    abstract:UNLABELLED:Oxaliplatin (OPT), a third-generation platinating agent, is currently being evaluated in a phase II clinical trial in head and neck cancer patients and in a phase I clinical trial in combination with paclitaxel (TXL). PURPOSE:The aim of this study was to investigate the pharmacokinetics and biological corre...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00280-002-0426-6

    authors: Liu J,Kraut E,Bender J,Brooks R,Balcerzak S,Grever M,Stanley H,D'Ambrosio S,Gibson-D'Ambrosio R,Chan KK

    更新日期:2002-05-01 00:00:00

  • Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.

    abstract:UNLABELLED:A hemopoietin with the ability to accelerate both platelet and granulocyte recovery after intensive chemotherapy would have great clinical utility. The recombinant fusion protein composed of human granulocyte-macrophage colony-stimulating factor and interleukin-3 (PIXY321), showed some promise in early adult...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s002800050733

    authors: Furman WL,Rodman JH,Tonda ME,Luo X,Arnold B,Marina N,Garrison L,Hanna R,Pratt CB,Meyer WH

    更新日期:1998-01-01 00:00:00

  • Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.

    abstract::We have previously demonstrated that overexpression of dihydrodiol dehydrogenase isoform 1 (DDH1) or DDH2 leads to the induction of drug resistance to platinum based drugs in human ovarian, lung, cervical and germ cell tumor cell lines. DDH belongs to a family of aldoketo reductases that are involved in the detoxifica...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-007-0554-0

    authors: Chen J,Adikari M,Pallai R,Parekh HK,Simpkins H

    更新日期:2008-05-01 00:00:00

  • Citrate enhances the protective effect of orally administered bismuth subnitrate against the nephrotoxicity of cis-diamminedichloroplatinum.

    abstract::Attenuation of the renal toxicity of cis-diamminedichloroplatinum (CDDP) is important in the use of this effective but cytotoxic anticancer agent. We have previously shown that the renal toxicity of CDDP can be efficiently reduced by the induction of metallothionein (MT) by preadministration of bismuth compounds in mi...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-003-0706-9

    authors: Kondo Y,Himeno S,Satoh M,Naganuma A,Nishimura T,Imura N

    更新日期:2004-01-01 00:00:00

  • Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.

    abstract::PSC-833, a non immunosuppressive analogue of cyclosporin A, is an effective modulator of the multidrug-resistant tumor phenotype. Since both PSC-833 and cyclosporin A also enhance the cytotoxicity of VP-16 against drug sensitive L1210 leukemia cells in vitro we compared these agents as modulators of VP-16 efficacy in ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050597

    authors: Slater LM,Sweet P,Stupecky M,Osann K

    更新日期:1997-01-01 00:00:00

  • Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme.

    abstract:PURPOSE:Although chemotherapeutic protocols that include chloroethylnitrosoureas (CENUs), such as 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and 1, 3-bis(2-chloroethyl)-1-nitrosourea (BCNU), have been a mainstay of treatment for glioblastomas, the clinical outcomes ha...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050023

    authors: Narita Y,Asai A,Kuchino Y,Kirino T

    更新日期:2000-01-01 00:00:00

  • Cimetidine attenuates vinorelbine-induced phlebitis in mice by militating E-selectin expression.

    abstract:PURPOSE:We investigated E-selectin expression in mice and rabbits with vinorelbine-induced phlebitis and the effect of cimetidine. To find the relationship between E-selectin expression and vinorelbine-induced phlebitis. METHODS:Mouse and rabbit model of vinorelbine-induced phlebitis was established by intravenous inf...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-014-2487-8

    authors: Wang Z,Ma L,Wang X,Cai H,Huang J,Liu J,Hu J,Su D

    更新日期:2014-08-01 00:00:00

  • Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments.

    abstract::Use of cross-sectional imaging to identify whole-body lean soft-tissue mass has recently emerged as an attractive prognostic factor for chemotherapy toxicities. Beyond that, there is increasing interest in use of lean soft-tissue mass as a more accurate method for dosing chemotherapy, as compared to body surface area....

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-018-3614-8

    authors: Hopkins JJ,Sawyer MB

    更新日期:2018-07-01 00:00:00

  • Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.

    abstract:PURPOSE:Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3009-7

    authors: Khawaja MR,Nick AM,Madhusudanannair V,Fu S,Hong D,McQuinn LM,Ng CS,Piha-Paul SA,Janku F,Subbiah V,Tsimberidou A,Karp D,Meric-Bernstam F,Lu KH,Naing A

    更新日期:2016-05-01 00:00:00

  • Methylene blue is more toxic to erythroleukemic cells than to normal peripheral blood mononuclear cells: a possible use in chemotherapy.

    abstract::Methylene blue (MB) is a phenothiazine with radio and photosensitizing properties and anti-tumoral activity. Our group has shown that MB was capable of inhibiting the in vitro growth of erythroleukemic cells with multidrug resistance (MDR). However, there are no studies comparing the cytotoxicity of this molecule for ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-005-1014-3

    authors: Kirszberg C,Rumjanek VM,Capella MA

    更新日期:2005-12-01 00:00:00

  • A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.

    abstract:PURPOSE:This phase I trial was initiated to evaluate the safety, pharmacokinetics (PK) and maximum tolerated dose (MTD) of the glycolytic inhibitor, 2-deoxy-D-glucose (2DG) in combination with docetaxel, in patients with advanced solid tumors. METHODS:A modified accelerated titration design was used. 2DG was administe...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-2045-1

    authors: Raez LE,Papadopoulos K,Ricart AD,Chiorean EG,Dipaola RS,Stein MN,Rocha Lima CM,Schlesselman JJ,Tolba K,Langmuir VK,Kroll S,Jung DT,Kurtoglu M,Rosenblatt J,Lampidis TJ

    更新日期:2013-02-01 00:00:00

  • Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer.

    abstract:PURPOSE:To evaluate the feasibility, toxicity and efficacy of the combination of docetaxel and mitomycin C as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:Thirty-eight patients with histologically confirmed, locally advanced or metastatic NSCLC were includ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0198-5

    authors: Feliu J,Martín G,Castro J,Sundlov A,Rodriguez-Jaráiz A,Casado E,Lomas M,Madroñal C,Galán A,Belda C,Gonzalez-Barón M

    更新日期:2006-10-01 00:00:00

  • Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

    abstract::Unidirectional blood-brain barrier transfer of the lipophilic anticancer agents vincristine and vinblastine was studied in anesthetized rats, using an isolated, in situ brain perfusion technique. Drug binding to plasma constituents was also measured. Despite the high lipophilicity of these agents (the log octanol/phys...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF02897227

    authors: Greig NH,Soncrant TT,Shetty HU,Momma S,Smith QR,Rapoport SI

    更新日期:1990-01-01 00:00:00